Terumo, PhotonPharma collaborate on cancer vaccine

By The Science Advisory Board staff writers

August 12, 2021 -- Medical device company Terumo Blood and Cell Technologies and cancer immunotherapy developer PhotonPharma announced they will work together on a therapeutic vaccine for solid tumors.

The companies have established a memorandum of understanding (MOU) to collaborate on the development of Innocell, a novel tumor-specific immunotherapy for solid-tumor malignancies, including breast cancer. The MOU is the first step of a longer-term collaboration, the companies said.

Illustration of a T-cell (orange) attaching to a cancer cell (blue).
Illustration of a T-cell (orange) attaching to a cancer cell (blue). Image courtesy of Terumo Blood and Cell Technologies and PhotonPharma.

PhotonPharma is using Terumo's Mirasol pathogen-reduction technology in the manufacturing process to inactivate viruses, bacteria, parasites, and white blood cells that may be present in collected blood products.

PhotonPharma is currently preparing an investigational new drug submission related to a phase I clinical trial of Innocel targeting triple-negative breast cancer. Terumo will supply Mirasol illuminators and single-use sets for the immunotherapy preparation process used in the clinical trial.

Auransa, Polaris Quantum tackle neglected women's diseases
Pharmaceutical artificial intelligence technology developer Auransa and quantum computing drug design firm Polaris Quantum Biotech have formed a research...
GEMoaB begins UniCAR-T PSMA clinical trial for solid tumors
GEMoaB has initiated its phase IA clinical trial with UniCAR-T prostate-specific membrane antigen (PSMA), an investigational UniCAR cellular immunotherapy,...
ImmunityBio touts preclinical data on NK cell therapy boosting product
ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma...
Samsung Biologics partners on antibody development, manufacturing
Samsung Biologics has announced that its contract development and manufacturing organization services have been selected by two companies for their antibody...
NBE Therapeutics begins clinical trial of antibody-drug conjugate
NBE Therapeutics has commenced a clinical study of its lead drug candidate, NBE-002, targeting receptor tyrosine kinase-like orphan receptor 1, for triple-negative...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2022
December 3-7
District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter